-
1 Comment
BioTelemetry, Inc is currently in a long term uptrend where the price is trading 34.6% above its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.0.
BioTelemetry, Inc's total revenue rose by 3.0% to $115M since the same quarter in the previous year.
Its net income has dropped by 18.9% to $7M since the same quarter in the previous year.
Finally, its free cash flow grew by 25.3% to $11M since the same quarter in the previous year.
Based on the above factors, BioTelemetry, Inc gets an overall score of 4/5.
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US42238H1086 |
| Sector | Healthcare |
| Industry | Health Information Services |
| Market Cap | 49M |
|---|---|
| PE Ratio | None |
| Target Price | 4.625 |
| Beta | -0.81 |
| Dividend Yield | None |
HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing ambulatory electrocardiogram solutions that enable the detection and monitoring of cardiac disease inside and outside a healthcare facility setting. The company develops three-dimensional vector images of cardiac electrical activity. It is developing HeartBeam AIMIGo, a credit card-sized cloud-based diagnostic software systems to address heart attack detection. The company was incorporated in 2015 and is based in Santa Clara, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BEAT using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
